VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ABT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ABTAbbott Laboratories
$104.71$182.4B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ABT logo

Abbott Laboratories

ABT
NYSE · Medical Devices
$104.71
At close - Nov 17, 4:00 PM EST - USD
Market Cap$182.38B
P/E38.7x
52W High$132.03
Volume5.77M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Margin Recovery Offsets Leverage Swings at Abbott

Abbott's gross margin expanded from 51.0% to 56.8% across the ten reported quarters, suggesting a mix shift toward higher-margin medical devices, but operating margin compressed to 10.4% in the latest quarter from 19.6% a year earlier, indicating operating expenses are absorbing much of that gain.

GrowthStable
ProfitabilityModerate
ValuationExpensive
TechnicalsHealthy
Explore valuation models
MARKET ACTION

ABT price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

+11% Peers

P/E is 11% above peer median

03

Market leadership

RS 54 · Avg

Average momentum (RS Rating: 54)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 21
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth has been uneven, with the latest quarter's 14.5% year-over-year increase following much slower prior growth, while gross margin improved to 56.8% but operating margin fell to 10.4% from 19.6% a year earlier, suggesting rising operating expenses are eroding gross profit gains.

Analyst Consensus+15.9% target
Buy(43 analysts)
33 Buy10 Hold0 Sell

The Bull Case

Upside Catalysts

Strong Acquisition Integration

The successful integration of Exact Sciences is expected to significantly boost Abbott's diagnostics business and overall growth trajectory.

Mid-Teens Growth in Cologuard

Analysts project mid-teens growth for Cologuard, supported by a substantial addressable market.

Favorable Feedback on New Products

New electrophysiology products like Volt PFA and TactiFlex Duo are receiving extremely favorable physician feedback, indicating potential for accelerated growth.

The Bear Case

Key Downside Risks

Nutrition Segment Declines

The Nutrition segment has faced declines due to incomplete pricing pass-through at retail, posing a risk to revenue.

EPS Dilution from Acquisition

The Exact Sciences acquisition is expected to dilute EPS, impacting earnings through 2026 and 2027 before becoming accretive.

Litigation Risks

Abbott faces litigation risks, including a recent $70 million jury award related to infant formula safety, with hundreds of similar cases pending.

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ABT-13.66%
S&P 500 (^GSPC)+7.21%
1-Year Return
ABT-17.53%
S&P 500 (^GSPC)+10.03%
3-Year Return
ABT+12.30%
S&P 500 (^GSPC)+60.03%
5-Year Return
ABT-10.04%
S&P 500 (^GSPC)+55.63%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
38.7x
Forward P/EExpansion
19.0x
EV/EBITDA0th %ile
17.1x
FCF YieldCash Flow
4.2%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
38.7x
33.7x
100th· High
EV/EBITDA
17.1x
20.4x
0th· Low
Price/FCF
23.8x
29.6x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$74.71-28.7%
Base (Fair)$132.41+22.0%
Bull$223.37+113.3%
$74.71 Bear$132.41 Base$223.37 Bull
Current Market Price: $104.71
Trades at a 20.9% discount to Base DCF ($132.41)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$44.33B+5.7% YoY
Net income FY25
$6.52B-51.3% YoY
Free cash flow FY25
$7.39B+16.4% YoY
Operating margin FY25
18.2%+1.9 pts YoY
ROIC (FY25)10.5%
Avg ROIC 5Y12%
ROE (TTM)9%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 21, 2026
$1.42+0.0%
vs $1.42
$13.0B+0.2%
vs $13.0B
Q3 2026
Jul 16, 2026
$1.31+2.3%
vs $1.28
$12.6B+0.6%
vs $12.5B
Q2 2026
Apr 16, 2026
$1.15+0.9%
vs $1.14
$11.2B+1.5%
vs $11.0B
Q1 2026
Jan 22, 2026
$1.50+0.0%
vs $1.50
$11.5B-2.9%
vs $11.8B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
The Winners Inside SCHD - November 2026

The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.

Zacks Investment Research·1d ago
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.

GuruFocus·1d ago
Is ABT Overvalued? DCF Says Worth $76

On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a

Defense World·2d ago
11,649 Abbott Laboratories $ABT Shares Bought by AlTi Global Inc.

AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,789 shares of the healthcare product maker's stock after acquiring an additional 11,649 shares during the period. AlTi

Filtered for Abbott LaboratoriesMore Headlines
04

Compare before deciding

Benchmark ABT against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Abbott Laboratories (ABT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ABT logoABTAbbott LaboratoriesCurrent
$104.71$182.38B38.715.67%9.75%9%2.25%
MDT logoMDTMedtronic plc
$102.32$131.37B25.148.43%13.93%10.51%2.76%
BSX logoBSXBoston Scientific Corporation
$43.03$63.96B17.9019.87%16.56%13.74%—
BDX logoBDXBecton, Dickinson and Company
$215.42$59.36B51.61-10.91%5.66%3.67%1.93%
BAX logoBAXBaxter International Inc.
$25.76$13.3B-18.535.72%-6.23%-11.67%2.63%
EW logoEWEdwards Lifesciences Corporation
$105.43$60.71B59.6311.55%15.3%9.65%—

Compare ABT vs Peers

Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MDT

Most directly comparable listed peer for ABT.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ABT against a more recognizable public peer.

Peer Set

Compare Top 5

vs MDT, BSX, BDX, BAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ABT SEC Filings & Documents

Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 16, 2026·SEC

Material company update

Oct 21, 2026·SEC

Material company update

Oct 21, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 20, 2026·SEC

FY 2025

Feb 21, 2025·SEC

FY 2024

Feb 16, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 4, 2026·SEC

FY 2026

Apr 29, 2026·SEC

FY 2025

Oct 29, 2025·SEC

Get notified when ABT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ABT Frequently Asked Questions

Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Abbott Laboratories's revenue?

Abbott Laboratories (ABT) reported $48.23B in revenue over the trailing twelve months. Revenue was $44.33B in fiscal year 2025. That is 302% more than the $11.01B of fiscal year 1996.

How fast is Abbott Laboratories growing?

Abbott Laboratories (ABT) grew revenue by 10.0% over the trailing twelve months, compared with the twelve months before.

Is ABT profitable?

Yes. Abbott Laboratories (ABT) earned $4.70B in net income over the trailing twelve months (a 9.7% net margin).

Dividend & Returns
Does ABT pay dividends?

Yes. Abbott Laboratories (ABT) pays a dividend that yields 2.25% at the current price, a moderate yield.

What is ABT's return on equity?

Abbott Laboratories (ABT) had a return on equity (ROE) of 9.0% over the trailing twelve months. That is below the market's typical 10-15%.

What is Abbott Laboratories's free cash flow?

Abbott Laboratories (ABT) generated $7.65B in free cash flow over the trailing twelve months.

What if you invested $1,000 in ABT back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →